Novartis AG (VTX: NOVN) has recently received a number of price target changes and ratings updates:

  • 10/24/2017 – Novartis AG was given a new CHF 87 price target on by analysts at S&P Global. They now have a “neutral” rating on the stock.
  • 10/24/2017 – Novartis AG was given a new CHF 90 price target on by analysts at Baader Bank. They now have a “buy” rating on the stock.
  • 10/23/2017 – Novartis AG was given a new CHF 78 price target on by analysts at UBS AG. They now have a “neutral” rating on the stock.
  • 10/20/2017 – Novartis AG was given a new CHF 88 price target on by analysts at Morgan Stanley. They now have a “buy” rating on the stock.
  • 10/17/2017 – Novartis AG was given a new CHF 80 price target on by analysts at Goldman Sachs Group, Inc. (The). They now have a “neutral” rating on the stock.
  • 10/16/2017 – Novartis AG was given a new CHF 100 price target on by analysts at Jefferies Group LLC. They now have a “buy” rating on the stock.
  • 10/12/2017 – Novartis AG was given a new CHF 90 price target on by analysts at HSBC Holdings plc. They now have a “buy” rating on the stock.
  • 10/4/2017 – Novartis AG was given a new CHF 83.50 price target on by analysts at Deutsche Bank AG. They now have a “neutral” rating on the stock.
  • 9/19/2017 – Novartis AG was given a new CHF 90 price target on by analysts at HSBC Holdings plc. They now have a “buy” rating on the stock.
  • 9/7/2017 – Novartis AG was given a new CHF 90 price target on by analysts at HSBC Holdings plc. They now have a “buy” rating on the stock.
  • 8/28/2017 – Novartis AG was given a new CHF 87 price target on by analysts at Kepler Capital Markets. They now have a “buy” rating on the stock.
  • 8/28/2017 – Novartis AG was given a new CHF 78 price target on by analysts at UBS AG. They now have a “neutral” rating on the stock.

Novartis AG (VTX:NOVN) opened at 82.25 on Wednesday. The firm has a 50-day moving average price of CHK 83.12 and a 200-day moving average price of CHK 80.20. The firm has a market capitalization of CHK 192.70 billion and a price-to-earnings ratio of 30.03. Novartis AG has a one year low of CHK 67.40 and a one year high of CHK 85.40.

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.